Alterations in lipid signatures, including high abundances of phosphatidylglycerols and cardiolipins, have been associated with MYC as an oncogenic factor in lymphoma as well as renal and hepatocellular carcinoma,38,39,40,41 and c-MYC has been identified as a possible therapeutic target in platinum-resistant ovarian cancer.42 Thus, alterations in lipid signatures may help explain why patients with type II morphologic subtype tended to have a worse response to neoadjuvant chemotherapy, although this observation needs to be validated. The gene discussed is MYC; the disease is lymphoma.